Part 1: NSCLC harboring NRG1+ fusion for Non-Small Cell Lung Cancer Harboring Neuregulin 1 Fusion
This trial tests a new drug to treat lung and prostate cancers.
- Non-Small Cell Lung Cancer Harboring Neuregulin 1 Fusion
- Metastatic Castration Resistant Prostate Cancer
2 Primary · 15 Secondary · Reporting Duration: Every 8 weeks until study ends, approximately 2 years
4 Treatment Groups
Part 1: NSCLC harboring NRG1+ fusion
1 of 4
Part 1: mCRPC
1 of 4
Part 2: NSCLC harboring NRG1+ fusion
1 of 4
Part 2: mCRPC
1 of 4
90 Total Participants · 4 Treatment Groups
Primary Treatment: Part 1: NSCLC harboring NRG1+ fusion · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What risks can be associated with mCRPC Phase 1?
"Although there is some evidence of safety, no clinical data exists regarding Part 1: mCRPC efficacy. Thus, it scored a 2 on our team's scale ranging from 1 to 3." - Anonymous Online Contributor
How many participants have signed up for involvement in this research?
"Affirmative, the information available from clinicaltrials.gov specifies that this scientific trial is still recruiting volunteers to participate. It was first posted on November 17th 2022 and its data set has been updated most recently on the 21st of November 2022. The research necessitates 90 participants at a single site." - Anonymous Online Contributor
What is the purpose of this experiment?
"This clinical trial seeks to assess the efficacy, safety and tolerability of Zenocutuzumab in combination with Afatinib over a two year period. Primary measurements include response rate, frequency/nature of adverse events (CTCAE Version 5.0), Area Under Curve (AUC0-∞) for afatinib and Progression-Free Survival (PFS) per RECIST v1.1 as determined by local investigators." - Anonymous Online Contributor
Are there any opportunities currently available to participate in this research?
"Affirmative. According to the information provided on clinicaltrials.gov, this investigation is actively searching for participants and was initially posted on November 17th 2022 with a most recent update occurring four days later." - Anonymous Online Contributor